Who are Thymoglobuline Genzyme's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ATG Fresenius, Rabbit ATG, (Genzyme), rabbit ATG（Sanofi/Genzyme）, Thymoglobulin (ATG), Anti-human Thymoglobulin, Flu-ATG.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/thymoglobuline-genzyme.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Thymoglobuline Genzyme — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Thymoglobuline Genzyme (Thymoglobuline Genzyme) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Polyclonal antithymocyte globulin (ATG). Area: Immunology / Hematology / Transplantation.

marketed Polyclonal antithymocyte globulin (ATG) Multiple T-cell surface antigens (CD2, CD3, CD4, CD8, CD11a, CD18, CD25, HLA-DR, and others) Immunology / Hematology / Transplantation Small molecule Live · refreshed every 30 min

Target snapshot

Thymoglobuline Genzyme (Thymoglobuline Genzyme) — University Hospital, Basel, Switzerland. Thymoglobuline is a polyclonal antithymocyte globulin (ATG) that depletes T lymphocytes by binding to multiple T-cell antigens and triggering their destruction.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Thymoglobuline Genzyme TARGET	Thymoglobuline Genzyme	University Hospital, Basel, Switzerland	marketed	Polyclonal antithymocyte globulin (ATG)	Multiple T-cell surface antigens (CD2, CD3, CD4, CD8, CD11a, CD18, CD25, HLA-DR, and others)
ATG Fresenius	ATG Fresenius	University Hospital, Basel, Switzerland	marketed	Polyclonal antithymocyte globulin (ATG)	T-cell surface antigens (CD2, CD3, CD4, CD8, CD25, HLA-DR)
Rabbit ATG, (Genzyme)	Rabbit ATG, (Genzyme)	Jinan Military General Hospital	marketed	Polyclonal antithymocyte globulin (ATG)	T-cell surface antigens (CD2, CD3, CD4, CD8, HLA-DR)
rabbit ATG（Sanofi/Genzyme）	rabbit ATG（Sanofi/Genzyme）	Chinese PLA General Hospital	marketed	Polyclonal antithymocyte globulin (ATG)	Multiple T-cell surface antigens (CD2, CD3, CD4, CD8, HLA-DR, and others)
Thymoglobulin (ATG)	Thymoglobulin (ATG)	M.D. Anderson Cancer Center	marketed	Polyclonal antithymocyte globulin (ATG)	Multiple T-cell antigens (CD2, CD3, CD4, CD8, CD11a, CD18, CD25, HLA-DR)
Anti-human Thymoglobulin	Anti-human Thymoglobulin	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	marketed	Polyclonal antithymocyte globulin (ATG)	T-cell surface antigens (CD2, CD3, CD4, CD8, HLA-DR)
Flu-ATG	Flu-ATG	Cooperative Study Group A for Hematology	phase 3	Polyclonal antithymocyte globulin (ATG)	T lymphocytes (CD2, CD3, CD4, CD8, and other T-cell surface antigens)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Polyclonal antithymocyte globulin (ATG) class)

University Hospital, Basel, Switzerland · 2 drugs in this class
Chinese PLA General Hospital · 1 drug in this class
Cooperative Study Group A for Hematology · 1 drug in this class
Jinan Military General Hospital · 1 drug in this class
M.D. Anderson Cancer Center · 1 drug in this class
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Thymoglobuline Genzyme — Competitive Intelligence Brief. https://druglandscape.com/ci/thymoglobuline-genzyme. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab